Literature DB >> 28834486

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

Jeremy S Abramson1, Brianne McGree1, Sarah Noyes1, Sean Plummer1, Curtis Wong1, Yi-Bin Chen1, Edwin Palmer2, Tina Albertson3, Judith A Ferry2, Isabel C Arrillaga-Romany4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28834486     DOI： 10.1056/NEJMc1704610

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  58 in total

Review 1.  Adipocyte and lipid metabolism in cancer drug resistance.

Authors:  Yihai Cao
Journal:  J Clin Invest       Date:  2019-07-02       Impact factor: 14.808

Review 2.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

3.  BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Authors:  Eric L Smith; Sham Mailankody; Mette Staehr; Xiuyan Wang; Brigitte Senechal; Terence J Purdon; Anthony F Daniyan; Mark B Geyer; Aaron D Goldberg; Elena Mead; Bianca D Santomasso; Jonathan Landa; Andreas Rimner; Isabelle Riviere; Ola Landgren; Renier J Brentjens
Journal:  Cancer Immunol Res       Date:  2019-05-21       Impact factor: 11.151

Review 4.  Introduction of novel agents in the treatment of primary CNS lymphoma.

Authors:  Christian Grommes; Lakshmi Nayak; Han W Tun; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 5.  Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.

Authors:  Bryan D Choi; Marcela V Maus; Carl H June; John H Sampson
Journal:  Clin Cancer Res       Date:  2018-11-16       Impact factor: 12.531

Review 6.  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

Authors:  Gavin P Dunn; Timothy F Cloughesy; Marcela V Maus; Robert M Prins; David A Reardon; Adam M Sonabend
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

7.  Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.

Authors:  Maria Ormhøj; Irene Scarfò; Maria L Cabral; Stefanie R Bailey; Selena J Lorrey; Amanda A Bouffard; Ana P Castano; Rebecca C Larson; Lauren S Riley; Andrea Schmidts; Bryan D Choi; Rikke S Andersen; Oriane Cédile; Charlotte G Nyvold; Jacob H Christensen; Morten F Gjerstorff; Henrik J Ditzel; David M Weinstock; Torben Barington; Matthew J Frigault; Marcela V Maus
Journal:  Clin Cancer Res       Date:  2019-08-22       Impact factor: 12.531

8.  Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.

Authors:  Christine E Brown; Brenda Aguilar; Renate Starr; Xin Yang; Wen-Chung Chang; Lihong Weng; Brenda Chang; Aniee Sarkissian; Alfonso Brito; James F Sanchez; Julie R Ostberg; Massimo D'Apuzzo; Behnam Badie; Michael E Barish; Stephen J Forman
Journal:  Mol Ther       Date:  2017-10-05       Impact factor: 11.454

Review 9.  CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Authors:  Mohamad Mohty; Jordan Gautier; Florent Malard; Mahmoud Aljurf; Ali Bazarbachi; Christian Chabannon; Mohamed A Kharfan-Dabaja; Bipin N Savani; He Huang; Saad Kenderian; Arnon Nagler; Miguel-Angel Perales
Journal:  Leukemia       Date:  2019-11-05       Impact factor: 11.528

Review 10.  On point in primary CNS lymphoma.

Authors:  Mazie Tsang; Joseph Cleveland; James L Rubenstein
Journal:  Hematol Oncol       Date:  2020-07-03       Impact factor: 5.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.